Indazole Compounds as 5-HT4 Receptor Agonists for Alzheimer's
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease primarily address late-stage symptoms and do not target the underlying cellular mechanisms, such as the generation of neurotoxic amyloid β-protein, and no 5-HT4 receptor agonists or partial agonists have been marketed for dementia-related disorders despite their potential utility in various psychiatric and cognitive disorders.
Innovation Solution
Development of novel 5-HT4 receptor agonists, including specific indazole compounds and their stereoisomers and pharmaceutically acceptable salts, which can be used to treat Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder, Huntington's disease, Parkinson's disease, and other psychiatric disorders by targeting the 5-HT4 receptor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (acetylcholine esterase inhibitors) are used for Alzheimer's disease, then cognitive deficits and memory loss are improved, but the treatment only addresses late-stage symptoms and does not target underlying cellular mechanisms, with benefits maintained only for up to 36 months
Solution Approach 1:
The patent changes the mechanism of action parameter from acetylcholine esterase inhibition to 5-HT4 receptor agonism, enabling treatment that targets underlying cellular mechanisms (amyloid β-protein generation) rather than just symptoms, potentially extending therapeutic benefit duration beyond 36 months
Solution Approach 2:
The patent introduces 5-HT4 receptor agonists as an intermediary mechanism between external treatment and internal cellular processes, specifically targeting the 5-HT4 receptor to modulate amyloid β-protein generation and improve cognitive functions
2Reliability
If 5-HT4 receptor agonists are developed for dementia-related disorders, then treatment effectiveness for various psychiatric and cognitive disorders is improved, but no such compounds have been marketed despite their potential utility
Solution Approach 1:
The patent performs preliminary research and development of 5-HT4 receptor agonists with specific chemical structures (indazole compounds), establishing their pharmacological activity and safety profile before market launch, thereby enabling future commercialization for treating Alzheimer's disease and other dementia-related disorders
Data Source
AI summary
The present invention relates to novel indazole compounds of the Formula (I), wherein, R1 is alkyl or cycloalkyl; (Formula II) including their stereoisomers and their pharmaceutically acceptable salts. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to 5-Hydroxy-tryptamine 4 (5-HT4) receptor agonists.